Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
Feature|Articles|February 20, 2026
Understanding the Biological and Social Complexities of Triple-Negative Breast Cancer
Author(s)Sabrina Serani
Fact checked by: Samilia Obeng-Gyasi, MD, MPH, Paige Britt
How ancestry, neighborhood stress and chemo side effects shape TNBC outcomes—and why immunotherapy and tailored care can narrow survival gaps.
Advertisement
Advertisement
In the landscape of oncology, triple-negative breast cancer (TNBC) remains one of the most challenging subtypes to treat due to its aggressive nature and the lack of traditional hormonal targets. However, for Samilia Obeng-Gyasi, MD, MPH, a surgical oncology specialist at The James, The Ohio State University Comprehensive Cancer Center, the challenge is not just biological; it is deeply rooted in ancestry, social environment, and patient experience.
Related to this article
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
Elinzanetant, already approved for menopause-related VMS, is being considered to address hot flashes associated with adjuvant breast cancer endocrine therapy.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
Advertisement
Advertisement